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ABSTRACT
Background    Hepatocellular carcinoma (HCC) in pa-
tients without hepatitis B (HBV) and -C virus (HCV) 
infection are increasing in Japan. Method for detecting 
high-risk liver diseases of HCC in general population 
has still not been established. Liver stiffness measure-
ment (LSM) and Controlled Attenuation Parameter 
(CAP) using transient elastography (TE; FibroScan Sys-
tem) are useful for detecting liver fibrosis and steatosis. 
The aim of this study is to clarify TE for risk assessment 
of HCC in general population.
Methods    This cross-sectional study was performed 
for residents aged ≥ 40 years in an intermountain town 
in Japan with a population of 3,493. Blood laboratory 
testing included tumor markers, abdominal ultrasound 
(AUS), and TE was performed. 
Results    Among 175 subjects (64 men, 111 women), 
TE was evaluated and three patients with HCC were 
detected by AUS. For detecting HCC, the cut-off value 
of LSM was 5.3 kPa sensitivity 100%, specificity 75%, 
AUROC 0.88). The combination of LSM and CAP 
(LSM > 5.3 kPa with any CAP and CAP > 248 dB/m 
with any LSM) could detect the high-risk liver diseases 
of HCC (HCC, nonalcoholic fatty liver/steatohepatitis, 
HBV or HCV related chronic viral hepatitis with alanine 
transaminase (ALT) > 30 IU/L for men or > 19 IU/L for 
women or cirrhosis of any cause) with high sensitivity 
(sensitivity 90%, specificity 55%, positive predictive val-
ue 10%, negative predictive value 99%, P = 0.006). 
Conclusion    The combination of LSM and CAP can 
be useful in detecting high-risk liver diseases of HCC 
out of general population.
Key words    controlled attenuation parameter, liver 
stiffness measurement, transient elastography, transab-
dominal ultrasound
Hepatocellular carcinoma (HCC), mainly related to hep-
atitis C virus (HCV) infection, is a major disease entity 
with high mortality in Japan.1 Therefore, screening for 
hepatitis virus infection had already been performed at 
periodical health check-ups by a 5-year national project 
from 2002 to 2006 in Japan.2, 3 However, only about 
60% of these viral positives were admitted to hospitals.4 
The early detection of HCC has not yet been achieved 
satisfactorily. Recently, the patients without viral in-
fection also have increased in 5 to 20% in Japan,5 and 
direct-acting antivirals are estimated to eradicate most 
of the HCV in the near future.6 Hence, establishing a 
new diagnostic method regardless of viral infection is a 
crucial issue. 
 A mass-screening program for HCC has never been 
established in Japan. Although direct screening for all 
people with abdominal ultrasonography (AUS) is ideal, 
mass screening is hindered by its slow process (about 15 
minutes per person) and cost (around 5000 yen per per-
son). 
 Liver fibrosis has been reported to be correlated with 
risk of HCC.7 Detecting liver steatosis is also important 
for diagnosing non-alcoholic steatohepatitis (NASH) as 
a risk of HCC without viral infection.8 In this regard, 
liver stiffness measurement (LSM) and Controlled At-
tenuation Parameter (CAP) using transient elastography 
(TE; FibroScan System, Echosens SA, Paris, France) 
can detect non-invasive liver fibrosis and steatosis, re-
spectively.9–11 They can be measured at the same time. 
Both LSMs between 7 kPa to 12.5 kPa and > 12.5 kPa 
are considered as an optimized cutoff value to detect 
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significance to sever fibrosis (F2–F3) and cirrhosis (F4) 
respectively.9 Recently, several reports have demonstrat-
ed that LSM is useful in detection of cirrhosis out of 
the general population.12–15 CAP is also reported to be 
significantly correlated with steatosis found by AUS in 
the general population.16 However, to our knowledge, 
there are no reports evaluating both parameters in HCC 
screening. The aim of this study is to clarify TE for risk 
assessment of HCC in general population. 
SUBJECTS AND METHODS
Subjects
Firstly, we planned the HCC screening program using 
tumor markers (alpha-fetoprotein; AFP and des-γ-car-
boxy prothrombin; DCP) and AUS. Subjects with abnor-
mal findings by AUS and/or elevation in tumor markers 
(AFP > 10ng /mL, DCP > 40 mAU/mL) were underwent 
further examinations. The evaluation of sonographic 
findings was based on the guideline edited by the Jap-
anese society of gastrointestinal cancer screening.17 In 
both June 2014 and January 2015, this program was 
performed for residents of the age of 40 or more in an 
intermountain town in Japan with a population of 3,493 
(population of subjects aged 40 or more was 74.2%). 
About 40% of the residents aged ≥ 40 of the town were 
already checked for hepatitis B surface antigen (HBs-
Ag) and hepatitis C virus antibody through the national 
health project,2, 3 and these data were available. On the 
same day of the HCC screening program, each applied 
resident had undergone interviews (alcohol consumption, 
smoking, comorbidity; diabetes /hypertension/hyper-
lipidemia), anthropometric measurements (height and 
weight), blood laboratory tests [aspartate aminotransfer-
ase (AST), alanine aminotransferase (ALT), gamma-glu-
tamyl transferase (GGT), AFP, and DCP], AUS, and TE. 
Drinkers and smokers were defined as alcohol consump-
tion ≥ 20 g/day, and current and former smokers who 
have more than a 30-pack-per-year history of smoking, 
respectively.18, 19 Body mass index (BMI) was calculated 
as the weight (kg) divided by height (m) squared (kg/
m2). TE was performed by FibroScan 502 equipped 
with M-probe (Echosens SA, Paris, France). TE was 
measured through the skin between the rib bones at the 
level of the right lobe of the liver in the supine position 
without assistance by AUS. LSM was expressed in kilo-
pascal (kPa) and the median value of 10 measurements 
was used. At least 10 valid measurements with success 
rate > 60% and interquartile range/median liver stiffness 
ratio < 30% were adapted.20, 21 CAP was also obtained 
simultaneously. We used the median of individual CAP 
values expressed in decibels per meter (dB/m). We de-
fined the high-risk liver diseases as HCC, hepatitis B vi-
rus (HBV) and hepatitis C virus (HCV) induced chronic 
viral hepatitis with ALT > 30 IU/L for men or > 19 IU/
L for women, nonalcoholic fatty liver disease (NAFLD)/
steatohepatitis (NASH) and cirrhosis of any causes. 
Ethical Considerations
The study protocol confirmed to the ethical guidelines 
of the 1975 Declaration of Helsinki as revised in 2000 
and was approved by the ethics committee of the Tottori 
University (No. 2438). Subjects were enrolled after giv-
ing their written informed consent. 
Statistical analysis
Data are expressed as median (range) or mean ± SD. 
Statistical analyses for significant differences among 
the groups were performed using the chi-square test, 
the Mann-Whitney’s U test, or the Kruskal-Wallis test. 
Correlations were calculated using Spearman’s rank cor-
relation coefficient. Multivariate analysis was performed 
using logistic regression model. All statistical analyses 
were performed using StatFlex (Windows ver 6.0; Ar-
tech, Osaka, Japan). Statistical significance was set at P 
< 0.05. 
RESULTS
Background of Subjects
We evaluated 181 subjects (65 men, 116 women) in the 
HCC screening program. In this program, AUS detected 
three patients (1.7%) with HCC out of 181 subjects in 
combination with positive tumor markers. The median 
age was 70 (40–81) years old, the median body mass in-
dex (BMI) was 26.7 (15–35) kg/m2, diabetes in 19 cases 
(11%), hypertension in 70 cases (38.7%) hyperlipidemia 
in 61 cases (33.7%) and viral hepatitis in 16 cases (HBV 
in 2, HCV in 14). Drinkers and smokers were in 36 cas-
es (19.9%) and in 38 cases (21%), respectively (Table 1). 
Transient elastography in the HCC screening pro-
gram
TE could be analyzed in 175 subjects because six sub-
jects were unmeasurable. The average exam duration 
was 138 ± 106 second, average success rate was 84 ± 
23%, the median of LSM was 4.4 (2–27.7) kPa, 7–12.5 
kPa in 11 cases (6%), and more than 12.5 kPa in 6 cases 
(3%) (Table 2). Six (35.3%) of 17 subjects with LSM > 7 
kPa had HCV infection. The median LSM values were 
significantly higher in subjects with BMI ≥ 25 kg/m2, 
hepatitis virus infection, habitual smoking, or hyperten-
sion than those without these backgrounds (Table 3). On 
the other hand, the median CAP was 224 (100–389) dB/
m (Table 2) and CAP values were significantly higher in 
subjects with BMI > 25 kg/m2 and fatty liver detected by 
108
T. Sugihara et al.
Table 1. Clinical findings in HCC screening program 
Subjects n = 181
Gender (male:female) 65:116
Age (years) 70 (40–81)
BMI* (kg/cm2) 26.7 (15–35)
> 25 kg/cm2 47 (26%)
HCC 3 (  1.7%)
Etiology**
HBV infection 2 (  1.1%)
HCV infection 14 (  7.7%)
Alcohol consumption (≥ 20 g/day) 36 (19.9%)
Smoking (≥ 30 pack-year) 38 (21%)
Comorbidity
Diabetes 19 (10.5%)
Hypertension 70 (38.7%)
Hyperlipidemia 61 (33.7%)
Data are expressed as median (range). *Lacked in 2 persons. 
**Hepatitis virus infection was checked by hepatitis B surface 
antigen (HBs-Ag) and HCV antibody.
BMI; body mass index, HBV, hepatitis B virus; HCC, hepatocel-
lular carcinoma; HCV, hepatitis C virus. 
Table 2. Results of transient elastography
n = 181
Success measurement 175 (96.7%)
Exam duration (s) 138 ± 106
Success rates (%) 84 ± 23
LSM (kPa) 4.4 (2–27.7)
7–12.5 kPa 11 (6%)
≥ 12.5 kPa 6 (3%)
CAP (dB/m) 224 (100–389)
Data are expressed as mean ± SD or median (range).
CAP, controlled attenuation parameter; LSM, liver stiffness mea-
surement.
Table 3. Differences of LSM and CAP according to clinical parameters
n = 175 LSM (kPa) P CAP (dB/m) P
Gender Male:Female 64:111 4.5 (2–21.8):4.4 (2.2–27.7) ns 221 (100–389):224 (100–380) ns
Age (< 60:≥ 60 yo) 32:143 4.4 (2.2–11.8):4.5 (2–27.7) ns 230 (133–389):223 (100–380) ns
BMI (< 25:≥ 25) 129:44* 4.3 (2–21.8):4.9 (2.3–27.7) 0.010 215 (100–365):256 (100–289) < 0.001
Hepatitis virus infection (No:Yes) 160:15 4.4 (2–27.7):6.0 (2.3–21.8) 0.026 226 (100–389):213 (152–314) ns
Alcohol (< 20:≥ 20 g/day) 139:36 4.5 (2–27.7):4.35 (2.2–21.8) ns 224 (100–380):214 (100–389) ns
Smoking (< 30:≥ 30 py) 139:36 4.4 (2–27.7):5.0 (2.9–21.8) 0.025 222 (100–389):231 (100–337) ns
DM (No:Yes) 156:19 4.4 (2–27.7):4.4 (2.3–11.8) ns 223 (100–389):247 (100–312) ns
Hyperlipidemia (No:Yes) 115:60 4.5 (2–27.7):4.4 (2.2–16) ns 217(100–389):247(100–331) ns
Hypertension (No:Yes) 108:67 4.4 (2–13):4.9 (2.2–27.7) 0.031 222 (100–380):229 (100–389) ns
Fatty liver by AUS (No:Yes) 143:32 4.4 (2–27.7):4.9 (2.3–16) ns 218 (100–365):269 (206–389) < 0.001
*Lacked in 2 persons.
AUS, abdominal ultrasonography; BMI, body mass index; CAP, controlled attenuation parameter; DM, diabetes mellitus; LSM, liver 
stiffness measurement; ns, not significant; py, pack-year; yo, year-old.
AUS (Table 3). The subjects were divided into quartiles 
Q1 to Q4, according to CAP values: Q1, < 195; Q2, 195–
223; Q3, 224–263; and Q4, ≥ 264 dB/m. Among all the 
patients, the LSM values were significantly higher in Q4 
[4.85 (2.3–16) kPa] compared with Q1 [4.5 (2–13) kPa] 
and Q3 [3.8 (2.2–20.2) kPa] (P = 0.02) (Fig. 1A). There 
was no significant correlation between CAP values and 
LSM values (r = 0.06, P = 0.11) (Fig. 1B). The only one 
case diagnosed as NASH demonstrated LSM 27.7 kPa 
and CAP 208 dB/m.
LSM in HCC detection
For detecting HCC, the area under the receiver operat-
ing characteristic (AUROC) was 0.88. Using the cut-off 
value of LSM as 5.3 kPa, the sensitivity and specificity 
were 100% and 75%, respectively (Fig. 2). 
Combined parameter for detecting high-risk liver 
diseases of HCC
Then, we evaluated TE as a tool for detecting high-risk 
liver diseases of HCC (HCC, HBV and HCV related 
chronic hepatitis with ALT > 30 IU/L for men or >19 
IU/L for women, NAFLD/NASH or cirrhosis of any 
cause). We have defined a cut-off value of the CAP for 
the detection of fatty liver by AUS with abnormal ALT (> 
30 IU/L for men or > 19 IU/L for women) as 248 dB/m 
(AUROC 0.77) (Fig. 3), and set the combined parameter 
as LSM > 5.3 kPa with any CAP and CAP > 248 dB/m 
with any LSM. The parameter demonstrated high sensi-
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Fig. 1. Relations between LSM and CAP values.
(A)The subjects were divided into quartiles Q1 to Q4, according to CAP values: Q1, < 195; Q2, 195–223; Q3, 224–
263; and Q4, ≥ 264 dB/m. LSM values were significantly higher in Q4 [4.85 (2.3–16) kPa] compared with Q1 [4.5 
(2–13) kPa] and Q3 [3.8 (2.2–20.2) kPa] *P = 0.02 (B) There was no significant correlation between CAP values 
and LSM values (r = 0.06, P = 0.11). CAP, controlled attenuation parameter; LSM, liver stiffness measurement.
Fig. 2. ROC of the LSM values in detecting HCC.
For detecting HCC, the AUROC was 0.88. Cut-off values of 5.8 
kPa had 100% sensitivity and 75% specificity. AUROC, area un-
der the receiver operating characteristic CAP, controlled attenua-
tion parameter; LSM, liver stiffness measurement; ROC, receiver 
operating characteristic.
Fig. 3. ROC of the CAP values in detecting fatty liver by AUS 
with abnormal ALT.
For detecting fatty liver by AUS with abnormal ALT, the AUROC 
was 0.77. Cut-off values of 248 dB/m had 67% sensitivity and 
70% specificity. ALT, alanine aminotransferase; AUS, abdominal 
ultrasonography; AUROC, area under the receiver operating char-
acteristic; ROC, receiver operating characteristic.
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tivity in detecting the high-risk liver diseases [sensitivity 
90%, specificity 55%, positive predictive value (PPV) 
10%, negative predictive value (NPV) 99%, P = 0.006]. 
The combined parameter could detect 11 subjects [HCC 
(n = 3), chronic hepatitis B (n = 1), chronic hepatitis C (n 
=3), NAFLD (n = 2), NASH (n = 1) and cirrhosis (n = 1)]. 
The numbers of hepatitis virus infection, AST and ALT 
levels were significantly higher in the high-risk liver dis-
eases than in the others (Table 4). 
DISCUSSION
This study demonstrated the combined parameter of 
LSM and CAP is a sensitive, non-invasive, quick (about 
2 minutes average), and less expensive (around 2000 yen 
per person) tool in mass screening of high-risk liver dis-
eases. 
 The detection rate of HCC was low (1.7%) in the 
present study. The large cohort study for screening HCC 
using ultrasonography in Japan also demonstrated the 
incidence of HCC was 0.034% (39/113,992).22 Taking 
into consideration the low incidence of HCC in the gen-
eral population, it is fundamentally difficult to obtain 
enough sample size for multivariate analysis to predict 
HCC in such population. Therefore, this preliminary 
study aimed to evaluate TE for detecting high-risk liver 
diseases.
 Two (66.7%) out of three HCC subjects were HCV 
positive. The hepatitis virus screening is undoubtedly 
important for detecting HCC, however, these two pa-
tients with known HCV infection had not been indicated 
any HCCs until this study. Considering their significant-
ly higher LSM, to show ‘direct’ liver parameters of TE 
is expected to motivate patients to have ultrasonographic 
examination.
 Liver fibrosis has been reported to be closely relat-
ed with HCC.7 Several reports have also demonstrated 
LSM could indicate the presence of cirrhosis out of 
general population.12–15 The selected cutoff level of LSM 
(5.3 kPa) was relatively lower, however, the optimal 
cutoff value of LSM is still controversial because of its 
differences with etiologies.23 Furthermore, there are no 
optimal cutoff value for HCC screening.
 On the other hand, meta-analysis indicated that the 
median optimal cut-off value of CAP for stage 1 to 3 ste-
atosis were 232.5 (214–289) dB/m, 255 (233–311) dB/m, 
and 290 (266–318) dB/m, respectively.24 In the present 
study, we set the cutoff value of CAP as 248 dB/m from 
result of fatty liver diagnosed by AUS with abnormal 
ALT levels. It covers the stage 1-2 of steatosis.
 In this study, the obese subjects had higher LSM 
and higher CAP than non-obese subjects. Recent re-
port indicated that the LSM values increase according 
to CAP values, and increase the percentage of false 
positive.25 However, in the present study, there was no 
significant correlation between the two parameters. The 
LSM values were also significantly higher in smokers 
and subjects with hypertension. It has been reported that 
smoking increases hepatic fibrosis when associated with 
hepatitis virus infection or NAFLD.26, 27 In the present 
study, there were only two smokers with hepatitis virus 
Table 4. Differences between the subjects with and without high-risk liver diseases of HCC
Non high-risk (n = 164) High-risk (n = 11) P
Gender (male:female) 62:102 2:9 ns
Age (years) 70 (40–81) 69 (64–78) ns
BMI (kg/m2 ) 24.6 (15.0–34.3) 21.5 (17.9–28.6) ns
Hepatitis virus infection 8 (4.9%) 7 (63.6%) < 0.001
Alcohol consumption (≥ 20 g/day) 34 (20.7%) 2 (18.2%) ns
Smoking (≥ 30 pack-year)  34 (20.7%) 2 (18.2%) ns
DM 18 (11%) 1 (9.1%) ns
AST (IU/L) 23 (14–84) 32 (19–112) 0.001
ALT (IU/L) 17.5 (8–108) 38 (12–93) 0.002
GGT (mg/mL) 21 (9–278) 31 (13–80) ns
AFP (ng/mL) 2.8 (0.7–9.5) 3.1 (1.2–92) ns
DCP (mAU/L) 20 (10–281) 27 (10–110) ns
AFP, alpha-fetoprotein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; BMI, body mass index; CAP, controlled at-
tenuation parameter; DCP, des-γ-carboxy prothrombin; DM, diabetes mellitus; GGT, gamma glutamyl transferase; HCC, hepatocellular 
carcinoma; LSM, liver stiffness measurement; ns, not significant. 
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infection. Except for hepatitis virus infection, there was 
significant difference in LSM between non-smoker (n = 
126) and smoker (n = 34) [4.4 (2–27.7) vs 4.9 (2.9–10.4) 
kPa, P = 0.028]. CAP values were higher in smokers; 
however, the rate of fatty liver was not significantly higher 
in smokers. Moreover, alcohol consumption was higher in 
smokers; however, no additional influences in LSM were 
observed. Therefore, there is no convincing data to ex-
plain the relation between smoking and liver fibrosis. On 
the other hand, the subjects with hypertension had higher 
LSM. Recent reports have also indicated that hyperten-
sion is associated with NAFLD as metabolic syndrome.28 
Insulin resistance raises blood pressure through the acti-
vation of the sympathetic nerve system (SNS) 29 and the 
renin–angiotensin system (RAS).30 The up-regulation of 
SNS and RAS induces liver fibrosis.31, 32 Therefore, hyper-
tension can be considered as a part of risk of HCC. 
 Considering the high sensitivity (90%) and high 
NPPV (99%), the negativity of the combined parameter 
would rather effectively exclude the subjects who are 
supposed not to have high-risk liver disease. In mass 
screening settings, only the subjects with positive result 
of combined parameter should be performed further ex-
aminations including AUS.
 There were several limitations in this study. First, 
the sample size was small. Therefore, it was difficult to 
perform multivariate analysis. This is the first preliminary 
study to clarify the combination of TE parameters for risk 
assessment of HCC in general population, and it should be 
validated in a prospective large cohort. Second, six sub-
jects could not be measured by TE; therefore, they were 
excluded from this study. We used only M probe (3.5MHz), 
and its unmeasurable rate is reported as 11.6–18.4%, 
and is associated with BMI > 30 kg/m2,23, 33 or age > 50 
years.33 Although these 6 subjects (3%) had significantly 
higher median BMI than measurable subjects [23.6 vs 
26.2 kg/m2, P = 0.028], there was only one patient with 
BMI > 30 kg/m2. On the other hand, all the six subjects 
were > 50 years old. Nowadays, a new probe (XL probe, 
2.5MHz) has become available for obese or older sub-
jects. 23, 33 Further study with XL probe is needed.
 In conclusion, the present study demonstrated that 
the combination of LSM and CAP is a sensitive, non-in-
vasive, quick, and less expensive tool for detecting high-
risk liver diseases of HCC out of general population. 
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